Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers

Epilepsy and Behavior

Volumn 18, Issue 4, 2010, Pages 366-373

  Milovan, Denise ^a   Almeida, Luis ^b,c   Romach, Myroslava K ^a   Nunes, Teresa ^b   Rocha, José Francisco ^b   Sokowloska, Marta ^a   Sellers, Edward M ^a   Soares da Silva, Patrício ^b,d  

^a Kendle Early Stage   (Canada)

^b DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d University of Porto   (Portugal)

Author keywords

Antiepileptic drugs; Cognition; Eslicarbazepine acetate; Oxcarbazepine; Psychomotor performance

Indexed keywords

ESLICARBAZEPINE ACETATE; OXCARBAZEPINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANXIETY DISORDER; APPETITE; ARTHRALGIA; ARTICLE; ASTHENIA; ASTHENOPIA; ATTENTION DEFICIT DISORDER; BACKACHE; BLURRED VISION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMPUTER ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; DRUG SCREENING; DYSGEUSIA; DYSMENORRHEA; DYSPEPSIA; DYSPHASIA; DYSPNEA; EJACULATION DISORDER; EPIGASTRIC PAIN; EUPHORIA; EYELID ERYTHEMA; FACE PAIN; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HERPES ZOSTER; HUMAN; HYPESTHESIA; INSOMNIA; LETHARGY; MACULOPAPULAR RASH; MALAISE; MALE; MEMORY DISORDER; MORNING DOSAGE; MUSCLE TWITCH; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; OTALGIA; PENIS ERECTION; POLYURIA; PREVALENCE; PRURITUS; PSYCHOMOTOR ACTIVITY; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SKIN PAIN; SOMNOLENCE; SORE THROAT; STOMACH DISCOMFORT; THORAX PAIN; VISUAL DISORDER; XEROSTOMIA;

ADULT; ANTICONVULSANTS; ATTENTION; BLOOD PRESSURE; CARBAMAZEPINE; COGNITION; DIBENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; LEARNING; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 77955578218     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.04.022     Document Type: Article

References (30)

1. Rogawski M.A. Principles of antiepileptic drug action. Antiepileptic drugs 2002, 3-22. Lippincot Williams & Wilkins, Philadelphia. 5th ed. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.).
2. Ambrosio A.F., Soares-Da-Silva P., Carvalho C.M., Carvalho A.P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002, 27:121-130.
3. Benes J., Parada A., Figueiredo A.A., Alves PC, Freitas AP, Learmonth DA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10, 11- dihydro-5H-dibenz[b, f]azepine-5-carboxamide derivatives. J Med Chem 1999, 42:2582-2587.
4. Almeida L., Bialer M., Soares-da-Silva P. Eslicarbazepine acetate. The treatment of epilepsy 2009, 485-498. Blackwell, Oxford. 3rd ed. S. Shorvon, E. Perucca, J. Engel (Eds.).
5. Elger C., Halasz P., Maia J., Almeida L., Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009, 50:454-463.
6. Gil-Nagel A., Lopes-Lima J., Almeida L., Maia J., Soares-da-Silva P. Efficacy and safety of 800 and 1200mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009, 120:281-287.
7. Hufnagel A., Ben-Menachem E., Gabbai A.A., Maia J., Almeida L., Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 Study. Epilepsia 2009, vol. 50:104.
8. Meador K.J. Cognitive effects of epilepsy and of antiepileptic medications. The treatment of epilepsy: principles and practice 2004, 1215-1226. Lippincott Williams & Wilkins, Philadelphia. 4th ed. E. Wyllie (Ed.).
9. Shorvon S.D. Oxcarbazepine: a review. Seizure 2000, 9:75-79.
10. Schmidt D., Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav 2000, 1:396-405.
11. Sillanpää M.L. Carbamazepine and oxcarbazepine. The treatment of epilepsy: principles and practice 2001, 821-842. Lippincott Williams & Wilkins, Philadelphia. E. Wyllie (Ed.).
12. Wellington K., Goa K.L. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001, 15:137-163.
13. Meador K.J., Loring D.W., Vahle V.J., Ray PG, Werz MA, Fessler AJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005, 64:2108-2114.
14. Hindmarch I., Rigney U., Stanley N., Briley M. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 2000, 49:118-125.
15. Busto U., Kaplan H.L., Zawertailo L., Sellers E.M. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin Pharmacol Ther 1994, 55:451-463.
16. Sternberg S. High-speed scanning in human memory. Science 1966, 153:652-654.
17. Kelland D.Z., Lewis R.F. The Digit Vigilance Test: reliability, validity, and sensitivity to diazepam. Arch Clin Neuropsychol 1996, 11:339-344.
18. Pieters M.S., van Steveninck A.F., Schoemaker R.C., Kroon J.M., van Gerven J.M., Cohen A.F. The psychomotor effects of carbamazepine in epileptic patients and healthy volunteers. J Psychopharmacol 2003, 17:269-272.
19. Rey A. Léxamen clinique en psychologie 1964, Presses Universitaire de France, Paris.
20. Benton A.L. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968, 6:53-60.
21. Partington J.E., Leiter R.G. Partington's Pathway Test. Psychol Serv Centre Bull 1949, 1:9-20.
22. Almeida L., Falcão A., Maia J., Mazur D., Gellert M., Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005, 45:1062-1066.
23. Compendium of pharmaceuticals and specialties 2006, Trileptal®SPC, Canadian Pharmacists Association.
24. Strauss E., Sherman E.M., Spreen O. A compendium of neuropsychological tests: administration, norms, and commentary 2006, Oxford Univ. Press, New York. 3rd ed.
25. Hainzl D., Parada A., Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10, 11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 2001, 44:197-206.
26. Volosov A., Xiaodong S., Perucca E., Yagen B., Sintov A., Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999, 66:547-553.
27. Bialer M. Oxcarbazepine. Antiepileptic drugs 2002, 459-465. Lippincott Williams & Wilkins, Philadelphia. 5th ed. R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca (Eds.).
28. Almeida L., Potgieter J.H., Maia J., Potgieter M.A., Mota F., Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008, 64:267-273.
29. Araujo I.M., Ambrosio A.F., Leal E.C., Verdasca MJ, Malva JO, Soares-da-Silva P, et al. Neurotoxicity induced by antiepileptic drugs in cultured hippocampal neurons: a comparative study between carbamazepine, oxcarbazepine, and two new putative antiepileptic drugs, BIA 2-024 and BIA 2-093. Epilepsia 2004, 45:1498-1505.
30. Zheng T., Clarke A.L., Morris M.J., Reid C.A., Petrou S., O'Brien T.J. Oxcarbazepine, not its active metabolite, potentiates GABAA activation and aggravates absence seizures. Epilepsia 2009, 50:83-87.